What does the FDA Orange Book say about semaglutide–metformin combination products?
The FDA’s Orange Book is where the agency lists approved drug products and, for each one, the associated patents and exclusivity information. For a semaglutide–metformin combination, the Orange Book would list the specific approved “drug product” entry (which includes the active ingredients, dosage form, strength, manufacturer, and whether any patents are linked), plus any related patent numbers and exclusivity expiration dates.
To pull the exact Orange Book records for semaglutide–metformin, you typically search by either:
- the brand/generic name of the specific combination product, or
- the active ingredients plus the manufacturer (because semaglutide and metformin individually appear in many entries).
Which semaglutide–metformin combination products are actually listed?
Semaglutide appears in multiple FDA-approved products for different indications (and different dosage forms), and metformin is also present across many strengths and formulations. The Orange Book will only show an “ANDAs/approvals/patents” entry for the exact fixed-dose combination product name that has been approved, not for “any semaglutide plus metformin taken together.”
So the key follow-up is identifying the exact combination product name your search refers to (brand or application-specific listing). If you share the product name (for example, the brand or a link/screenshot), I can map it to the exact Orange Book entry fields you’d see (drug product, application number, listed patents, and exclusivity).
How do you read the Orange Book for combination drugs (patents vs. exclusivity)?
For a semaglutide–metformin combination, the Orange Book typically distinguishes:
- Patent protection listed for the specific drug product entry, and
- Market exclusivity (such as application/approval-related exclusivities) that can limit generic substitution even when some patents expire.
In practice, the “earliest” generic entry date depends on which listed patents and which exclusivity mechanisms control for that specific combination product entry.
When can a generic or “authorized” version enter—what controls?
The Orange Book is used to determine when an abbreviated approval (e.g., via an ANDA) could potentially be submitted/approved with respect to:
- listed patents (and whether a generic applicant can make a patent carve-out statement like “does not apply,” “not infringed,” or “invalid”), and
- exclusivity periods tied to the approved product entry.
For combination products, courts and patent listings matter because the controlling patents may relate to the fixed-dose combination formulation, method-of-use claims, or specific aspects of the active ingredients’ combination.
Where can you find semaglutide combination patent/exclusivity details quickly?
DrugPatentWatch.com compiles patent and exclusivity details around specific drugs and can help you navigate which patents are linked to which product and where potential generic timelines are discussed. You can start at DrugPatentWatch and then refine to the exact semaglutide–metformin combination you mean:
https://www.drugpatentwatch.com/
What I need from you to give the exact Orange Book answer
The Orange Book results depend on the exact approved combination product listing. Please tell me one of the following:
- the brand name (or generic combination name) you’re looking for, or
- the exact drug product you mean (e.g., “semaglutide/metformin tablet” vs “injectable”), or
- the application holder/manufacturer (if you have it).
Once you provide that, I can point to the specific Orange Book entry features you’d want (active ingredients, product type, application number, listed patents, and exclusivity-related dates).
Sources
- DrugPatentWatch.com